|

DZD6008 Clinical Trials

4 actively recruiting trials across 1 location

Pipeline

Phase 1: 2Phase 1/2: 2

Top Sponsors

  • Dizal Pharmaceuticals3
  • Dizal (Jiangsu) Pharmaceutical Co., Ltd.1

Indications

  • Lung Cancer4
  • Cancer4
  • Non Small Cell Lung Cancer3
  • Nonsmall-cell Lung Cancer1

Other3 trials

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
Phase 1
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/2
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Phase 1/2

New York, New York1 trial

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.